The drug can inhibit cellular growth and induce autophagy via the downregulation of the PI3K/AKT/mTOR pathway in the 786-O and ACHN cells of renal cell carcinoma. This evidence concerns the gene AKT1 and hereditary clear cell renal cell carcinoma.